Type,Section,Rule_ID,Drug_Medication,Condition_Disease,Rationale_Reason,Full_Text
STOPP,Section A: Indication of medication,1,Any drug prescribed without a clinical indication.,General/Unspecified,Review Manually,Any drug prescribed without a clinical indication.
STOPP,Section A: Indication of medication,2,"Any drug prescribed beyond the recommended duration,",where treatment duration is well defined.,Review Manually,"Any drug prescribed beyond the recommended duration, where treatment duration is well defined."
STOPP,Section A: Indication of medication,3,Any duplicate drug class prescription,"for daily regular use (as distinct from PRN use) e.g., two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants, antipsychotics, opioid analgesics",optimisation of monotherapy within a single drug class should be observed prior to considering a new agent,"Any duplicate drug class prescription for daily regular use (as distinct from PRN use) e.g., two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants, antipsychotics, opioid analgesics (optimisation of monotherapy within a single drug class should be observed prior to considering a new agent)."
STOPP,Section B: Cardiovascular System,1,Digoxin,for heart failure with normal systolic ventricular function,no clear evidence of benefit,Digoxin for heart failure with normal systolic ventricular function (no clear evidence of benefit)
STOPP,Section B: Cardiovascular System,2,Verapamil or diltiazem,with NYHA Class III or IV heart failure,"may worsen heart failure with reduced ejection fraction i.e., HFREF","Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure with reduced ejection fraction i.e., HFREF)."
STOPP,Section B: Cardiovascular System,3,Beta-blocker,in combination with verapamil or diltiazem,risk of heart block,Beta-blocker in combination with verapamil or diltiazem (risk of heart block).
STOPP,Section B: Cardiovascular System,4,"Ventricular rate-limiting drugs i.e., beta blocker, verapamil, diltiazem, digoxin","with bradycardia (< 50/min), type II heart block or complete heart block","risk of complete heart block, asystole","Ventricular rate-limiting drugs i.e., beta blocker, verapamil, diltiazem, digoxin with bradycardia (< 50/min), type II heart block or complete heart block (risk of complete heart block, asystole)."
STOPP,Section B: Cardiovascular System,5,Beta-blocker as monotherapy,"for uncomplicated hypertension i.e., not associated with angina pectoris, aortic aneurysm or other condition where beta-blocker therapy is indicated",no firm evidence of efficacy,"Beta-blocker as monotherapy for uncomplicated hypertension i.e., not associated with angina pectoris, aortic aneurysm or other condition where beta-blocker therapy is indicated (no firm evidence of efficacy)."
STOPP,Section B: Cardiovascular System,6,Amiodarone as first-line antiarrhythmic therapy,in supraventricular tachyarrhythmias,"higher risk of major side-effects than beta-blockers, digoxin, verapamil or diltiazem","Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of major side-effects than beta-blockers, digoxin, verapamil or diltiazem)."
STOPP,Section B: Cardiovascular System,7,Loop diuretic as first-line treatment,for hypertension unless there is concurrent heart failure requiring diuretic therapy,"safer, more effective alternatives available","Loop diuretic as first-line treatment for hypertension unless there is concurrent heart failure requiring diuretic therapy (safer, more effective alternatives available)."
STOPP,Section B: Cardiovascular System,8,Loop diuretic,"for dependent ankle oedema without clinical, biochemical or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure",leg elevation and /or compression hosiery usually more appropriate,"Loop diuretic for dependent ankle oedema without clinical, biochemical or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually more appropriate). 1"
STOPP,Section B: Cardiovascular System,9,Thiazide diuretic,"with current significant hypokalaemia (i.e., serum K+ < 3.0 mmol/l), hyponatraemia (i.e., serum Na+ < 130 mmol/l) hypercalcaemia (i.e., corrected serum calcium > 2.65 mmol/l) or with a history of gout","hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic","Thiazide diuretic with current significant hypokalaemia (i.e., serum K+ < 3.0 mmol/l), hyponatraemia (i.e., serum Na+ < 130 mmol/l) hypercalcaemia (i.e., corrected serum calcium > 2.65 mmol/l) or with a history of gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic)"
STOPP,Section B: Cardiovascular System,10,Loop diuretic,for treatment of hypertension with concurrent urinary incontinence,may exacerbate incontinence,Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may exacerbate incontinence).
STOPP,Section B: Cardiovascular System,11,"Centrally-acting antihypertensives e.g., methyldopa, clonidine, moxonidine, rilmenidine, guanfacine",General/Unspecified,centrally-active antihypertensives are generally less well tolerated by older people than younger people,"Centrally-acting antihypertensives e.g., methyldopa, clonidine, moxonidine, rilmenidine, guanfacine (centrally-active antihypertensives are generally less well tolerated by older people than younger people)"
STOPP,Section B: Cardiovascular System,12,Angiotensin-Converting Enzyme inhibitors (ACEIs) or Angiotensin Receptor Blockers,General/Unspecified,ARBs,"Angiotensin-Converting Enzyme inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs) in patients with hyperkalaemia i.e., serum K > 5.5 mmol/l."
STOPP,Section B: Cardiovascular System,13,"Aldosterone antagonists (e.g., spironolactone, eplerenone)","with concurrent potassium- conserving drugs (e.g., ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum potassium","risk of dangerous hyperkalaemia i.e., > 6.0 mmol/l – serum K should be monitored regularly, i.e., at least every 6 months","Aldosterone antagonists (e.g., spironolactone, eplerenone) with concurrent potassium- conserving drugs (e.g., ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum potassium (risk of dangerous hyperkalaemia i.e., > 6.0 mmol/l – serum K should be monitored regularly, i.e., at least every 6 months)."
STOPP,Section B: Cardiovascular System,14,"Phosphodiesterase type-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil)","in severe heart failure characterised by hypotension i.e., systolic BP < 90 mmHg, or concurrent nitrate therapy for angina",risk of cardiovascular collapse,"Phosphodiesterase type-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) in severe heart failure characterised by hypotension i.e., systolic BP < 90 mmHg, or concurrent nitrate therapy for angina (risk of cardiovascular collapse)."
STOPP,Section B: Cardiovascular System,15,Drugs that predictably prolong the QTc interval (QTc = QT/RR),"in patients with known with demonstrable QTc prolongation (to >450 msec in males and >470 msec in females), including quinolones, macrolides, ondansetron, citalopram (doses > 20 mg/day), escitalopram (doses > 10 mg/day), tricyclic antidepressants, lithium, haloperidol, digoxin, class 1A antiarrhythmics, class III antiarrhythmics, tizanidine, phenothiazines, astemizole, mirabegron",risk of life- threatening ventricular arrhythmias,"Drugs that predictably prolong the QTc interval (QTc = QT/RR) in patients with known with demonstrable QTc prolongation (to >450 msec in males and >470 msec in females), including quinolones, macrolides, ondansetron, citalopram (doses > 20 mg/day), escitalopram (doses > 10 mg/day), tricyclic antidepressants, lithium, haloperidol, digoxin, class 1A antiarrhythmics, class III antiarrhythmics, tizanidine, phenothiazines, astemizole, mirabegron (risk of life- threatening ventricular arrhythmias)."
STOPP,Section B: Cardiovascular System,16,Statins,for primary cardiovascular prevention in persons aged ≥ 85 and established frailty with expected life expectancy likely less than 3 years,lack of evidence of efficacy,Statins for primary cardiovascular prevention in persons aged ≥ 85 and established frailty with expected life expectancy likely less than 3 years (lack of evidence of efficacy).
STOPP,Section B: Cardiovascular System,17,"Long-term systemic i.e., non-topical NSAIDs","with known history of coronary, cerebral or peripheral vascular disease",increased risk of thrombosis,"Long-term systemic i.e., non-topical NSAIDs with known history of coronary, cerebral or peripheral vascular disease (increased risk of thrombosis)."
STOPP,Section B: Cardiovascular System,18,Long-term antipsychotics,"with known history of coronary, cerebral or peripheral vascular disease",increased risk of thrombosis,"Long-term antipsychotics with known history of coronary, cerebral or peripheral vascular disease (increased risk of thrombosis)."
STOPP,Section B: Cardiovascular System,19,NSAIDs or systemic corticosteroids,with heart failure requiring loop diuretic therapy,risk of exacerbation of heart failure,NSAIDs or systemic corticosteroids with heart failure requiring loop diuretic therapy (risk of exacerbation of heart failure).
STOPP,Section B: Cardiovascular System,20,Antihypertensive drugs,in severe symptomatic aortic stenosis,"risk of severe hypotension, syncope","Antihypertensive drugs in severe symptomatic aortic stenosis (risk of severe hypotension, syncope)."
STOPP,Section B: Cardiovascular System,21,Digoxin as first line treatment,for long-term (> 3 months) ventricular rate control in atrial fibrillation,increased mortality from long-term digoxin use; cardio-selective beta-blockers are generally preferable,Digoxin as first line treatment for long-term (> 3 months) ventricular rate control in atrial fibrillation (increased mortality from long-term digoxin use; cardio-selective beta-blockers are generally preferable). 2
STOPP,Section C: Coagulation System,1,Long-term aspirin at doses greater than 100mg per day,General/Unspecified,"increased risk of bleeding, no evidence for increased efficacy","Long-term aspirin at doses greater than 100mg per day (increased risk of bleeding, no evidence for increased efficacy)."
STOPP,Section C: Coagulation System,2,"Antiplatelet agents, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors","with concurrent significant risk of major bleeding, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding",high risk of bleeding,"Antiplatelet agents, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors with concurrent significant risk of major bleeding, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding (high risk of bleeding)."
STOPP,Section C: Coagulation System,3,"Aspirin plus clopidogrel as long-term secondary stroke prevention i.e., > 4 weeks,",unless the patient has a coronary stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial stenosis,no evidence of added long-term benefit over clopidogrel monotherapy,"Aspirin plus clopidogrel as long-term secondary stroke prevention i.e., > 4 weeks, unless the patient has a coronary stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial stenosis (no evidence of added long-term benefit over clopidogrel monotherapy)."
STOPP,Section C: Coagulation System,4,Antiplatelet agents,"in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with chronic atrial fibrillation, unless there is concurrent coronary artery stent(s) inserted or angiographically proven high grade (> 50%) coronary artery stenosis",no added benefit from antiplatelet agents,"Antiplatelet agents in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with chronic atrial fibrillation, unless there is concurrent coronary artery stent(s) inserted or angiographically proven high grade (> 50%) coronary artery stenosis (no added benefit from antiplatelet agents)."
STOPP,Section C: Coagulation System,5,Antiplatelet agents,"with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with stable coronary, cerebrovascular or peripheral arterial disease",no evidence of added benefit from dual therapy,"Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with stable coronary, cerebrovascular or peripheral arterial disease (no evidence of added benefit from dual therapy)."
STOPP,Section C: Coagulation System,6,Ticlopidine,in any circumstances,"clopidogrel and prasugrel have similar efficacy, stronger evidence and fewer side-effects","Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, stronger evidence and fewer side-effects)."
STOPP,Section C: Coagulation System,7,"Antiplatelet agents as alternatives to vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors",for stroke prevention in patients with chronic atrial fibrillation,no evidence of efficacy,"Antiplatelet agents as alternatives to vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors for stroke prevention in patients with chronic atrial fibrillation (no evidence of efficacy)."
STOPP,Section C: Coagulation System,8,"Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors","for first deep venous thrombosis without continuing provoking risk factors (e.g., thrombophilia) for longer than 6 months,",no proven added benefit,"Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous thrombosis without continuing provoking risk factors (e.g., thrombophilia) for longer than 6 months, (no proven added benefit)."
STOPP,Section C: Coagulation System,9,"Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors","for first pulmonary embolus without continuing provoking risk factors (e.g., thrombophilia) for longer than 12 months",no proven added benefit,"Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus without continuing provoking risk factors (e.g., thrombophilia) for longer than 12 months (no proven added benefit)."
STOPP,Section C: Coagulation System,10,"Nonsteroidal anti-inflammatory drugs (NSAIDs) and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors",in combination,risk of major gastrointestinal bleeding,"Nonsteroidal anti-inflammatory drugs (NSAIDs) and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination (risk of major gastrointestinal bleeding)."
STOPP,Section C: Coagulation System,11,Vitamin K antagonist as first-line anticoagulant,"for atrial fibrillation, unless there is concurrent metallic heart valve in-situ, moderate-to-severe mitral stenosis, or eGFR < 15 mls/min./1.73m2",direct thrombin inhibitors or factor Xa inhibitors are equally efficacious and safer than vitamin K antagonists,"Vitamin K antagonist as first-line anticoagulant for atrial fibrillation, unless there is concurrent metallic heart valve in-situ, moderate-to-severe mitral stenosis, or eGFR < 15 mls/min./1.73m2 (direct thrombin inhibitors or factor Xa inhibitors are equally efficacious and safer than vitamin K antagonists)."
STOPP,Section C: Coagulation System,12,Selective serotonin reuptake inhibitors (SSRIs),"in combination with Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitor with a previous history of major haemorrhage",increased risk of bleeding due to antiplatelet effects of SSRIs,"Selective serotonin reuptake inhibitors (SSRIs) in combination with Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitor with a previous history of major haemorrhage (increased risk of bleeding due to antiplatelet effects of SSRIs). 3"
STOPP,Section C: Coagulation System,13,"Direct thrombin inhibitor (e.g., dabigatran) and diltiazem or verapamil",General/Unspecified,increased risk of bleeding,"Direct thrombin inhibitor (e.g., dabigatran) and diltiazem or verapamil (increased risk of bleeding)."
STOPP,Section C: Coagulation System,14,"Apixaban, dabigatran, edoxaban, rivaroxaban and P-glycoprotein (P-gp) drug efflux pump inhibitors e.g., amiodarone, azithromycin, carvedilol, cyclosporin, dronedarone, itraconazole, ketoconazole (systemic), macrolides, quinine, ranolazine, tamoxifen, ticagrelor, verapamil",General/Unspecified,increased risk of bleeding,"Apixaban, dabigatran, edoxaban, rivaroxaban and P-glycoprotein (P-gp) drug efflux pump inhibitors e.g., amiodarone, azithromycin, carvedilol, cyclosporin, dronedarone, itraconazole, ketoconazole (systemic), macrolides, quinine, ranolazine, tamoxifen, ticagrelor, verapamil (increased risk of bleeding)."
STOPP,Section C: Coagulation System,15,Systemic oestrogens or androgens,with pervious history of venous thromboembolism,increased risk of recurrent venous thromboembolism,Systemic oestrogens or androgens with pervious history of venous thromboembolism (increased risk of recurrent venous thromboembolism).
STOPP,Section C: Coagulation System,16,Aspirin,for primary prevention in cardiovascular disease,no evidence of benefit,Aspirin for primary prevention in cardiovascular disease (no evidence of benefit).
STOPP,Section D: Central Nervous System,1,TriCyclic Antidepressants (TCAs),"in patients with dementia, narrow angle glaucoma, cardiac conduction abnormalities, prostatism, chronic constipation, recent falls, prior history of urinary retention or orthostatic hypotension",risk of worsening these conditions,"TriCyclic Antidepressants (TCAs) in patients with dementia, narrow angle glaucoma, cardiac conduction abnormalities, prostatism, chronic constipation, recent falls, prior history of urinary retention or orthostatic hypotension (risk of worsening these conditions)."
STOPP,Section D: Central Nervous System,2,Initiation of TriCyclic Antidepressants (TCAs) as first-line treatment,for major depression,higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs,Initiation of TriCyclic Antidepressants (TCAs) as first-line treatment for major depression (higher risk of adverse drug reactions with TCAs than with SSRIs or SNRIs).
STOPP,Section D: Central Nervous System,3,"Serotonin/noradrenaline reuptake inhibitors (SNRI’s e.g., venlafaxine, duloxetine) and severe hypertension i.e., systolic blood pressure > 180 mmHg +/- diastolic blood pressure > 105 mmHg",General/Unspecified,likely to make hypertension worse,"Serotonin/noradrenaline reuptake inhibitors (SNRI’s e.g., venlafaxine, duloxetine) and severe hypertension i.e., systolic blood pressure > 180 mmHg +/- diastolic blood pressure > 105 mmHg (likely to make hypertension worse)."
STOPP,Section D: Central Nervous System,4,Antipsychotics,"with moderate-marked antimuscarinic/anticholinergic effects (acepromazine, chlorpromazine, clozapine, flupenthixol, fluphenzine, levomepromazine, olanzapine, pipothiazine, promazine, thioridazine) with a history of lower urinary tract symptoms associated with benign prostatic hyperplasia or previous urinary retention",high risk of urinary retention,"Antipsychotics with moderate-marked antimuscarinic/anticholinergic effects (acepromazine, chlorpromazine, clozapine, flupenthixol, fluphenzine, levomepromazine, olanzapine, pipothiazine, promazine, thioridazine) with a history of lower urinary tract symptoms associated with benign prostatic hyperplasia or previous urinary retention (high risk of urinary retention)."
STOPP,Section D: Central Nervous System,5,Antipsychotics prescribed,for behavioural and psychological symptoms of dementia (BPSD) an unchanged dose for > 3 months without medication review,"increased risk of extrapyramidal side-effects and chronic worsening of cognition, increased risk of major cardiovascular morbidity and mortality","Antipsychotics prescribed for behavioural and psychological symptoms of dementia (BPSD) an unchanged dose for > 3 months without medication review (increased risk of extrapyramidal side-effects and chronic worsening of cognition, increased risk of major cardiovascular morbidity and mortality)."
STOPP,Section D: Central Nervous System,6,Selective serotonin re-uptake inhibitors (SSRI’s),"with current or recent significant hyponatraemia i.e., serum Na+ < 130 mmol/l",risk of exacerbating or precipitating hyponatraemia,"Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia i.e., serum Na+ < 130 mmol/l (risk of exacerbating or precipitating hyponatraemia)."
STOPP,Section D: Central Nervous System,7,Selective serotonin re-uptake inhibitors (SSRI’s),with current or recent significant bleeding,risk of exacerbation or recurrence of bleeding due to antiplatelet effects of SSRI’s,Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant bleeding (risk of exacerbation or recurrence of bleeding due to antiplatelet effects of SSRI’s).
STOPP,Section D: Central Nervous System,8,Benzodiazepines,for ≥ 4 weeks,"no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly","Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for more than 4 weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly). 4"
STOPP,Section D: Central Nervous System,9,Benzodiazepines,for agitated behaviour or psychotic symptoms of dementia,no evidence of efficacy,Benzodiazepines for agitated behaviour or psychotic symptoms of dementia (no evidence of efficacy).
STOPP,Section D: Central Nervous System,10,Benzodiazepines,for insomnia for ≥ 2 weeks,"high risk of dependency, increased risk of falls, fractures and road traffic accidents","Benzodiazepines for insomnia for ≥ 2 weeks (high risk of dependency, increased risk of falls, fractures and road traffic accidents)."
STOPP,Section D: Central Nervous System,11,"Z-drugs (zolpidem, zopiclone, zaleplon)",for insomnia for ≥ 2 weeks,"increased risk of falls, fractures","Z-drugs (zolpidem, zopiclone, zaleplon) for insomnia for ≥ 2 weeks (increased risk of falls, fractures)."
STOPP,Section D: Central Nervous System,12,"Antipsychotics (i.e., other than clozapine or quetiapine)",in those with parkinsonism or Dementia with Lewy Bodies,risk of severe extra-pyramidal symptoms,"Antipsychotics (i.e., other than clozapine or quetiapine) in those with parkinsonism or Dementia with Lewy Bodies (risk of severe extra-pyramidal symptoms)."
STOPP,Section D: Central Nervous System,13,"Anticholinergic/antimuscarinic drugs (biperiden, orphenadrine, procyclidine, trihexyphenidyl) to treat extra-pyramidal side-effects of antipsychotic medications",General/Unspecified,risk of anticholinergic toxicity,"Anticholinergic/antimuscarinic drugs (biperiden, orphenadrine, procyclidine, trihexyphenidyl) to treat extra-pyramidal side-effects of antipsychotic medications (risk of anticholinergic toxicity)."
STOPP,Section D: Central Nervous System,14,Drugs,"with potent anticholinergics/antimuscarinic effects** in patients with delirium or dementia (risk of exacerbation of cognitive impairment). ** Commonly prescribed drugs with potent anticholinergic/ antimuscarinic effects include tricyclic antidepressants (e.g., amitriptyline, doxepin, impramine, nortriptyline), antipsychotics (chlorpromazine, clozapine, thioridazine), first generation antihistamines (e.g., diphenhydramine, chlorpheniramine), bladder anti-spasmodics","e.g., tolterodine, oxybutynin","Drugs with potent anticholinergics/antimuscarinic effects** in patients with delirium or dementia (risk of exacerbation of cognitive impairment). ** Commonly prescribed drugs with potent anticholinergic/ antimuscarinic effects include tricyclic antidepressants (e.g., amitriptyline, doxepin, impramine, nortriptyline), antipsychotics (chlorpromazine, clozapine, thioridazine), first generation antihistamines (e.g., diphenhydramine, chlorpheniramine), bladder anti-spasmodics (e.g., tolterodine, oxybutynin), hyoscine, procyclidine, benzatropine, tizanidine."
STOPP,Section D: Central Nervous System,15,Antipsychotics,in patients with behavioural and psychological symptoms of dementia (BPSD) for longer than 12 weeks unless BPSD symptoms are severe and other non- pharmacological treatments have failed,"increased risk of stroke, myocardial infarction","Antipsychotics in patients with behavioural and psychological symptoms of dementia (BPSD) for longer than 12 weeks unless BPSD symptoms are severe and other non- pharmacological treatments have failed (increased risk of stroke, myocardial infarction)."
STOPP,Section D: Central Nervous System,16,"Antipsychotics as hypnotics,",unless sleep disorder is due to psychosis or BPSD effects of dementia,"not recommended in summary of product characteristics; increased risk of confusion, hypotension, extra-pyramidal side effects, falls","Antipsychotics as hypnotics, unless sleep disorder is due to psychosis or BPSD effects of dementia (not recommended in summary of product characteristics; increased risk of confusion, hypotension, extra-pyramidal side effects, falls)."
STOPP,Section D: Central Nervous System,17,Acetylcholinesterase inhibitors,"with a known history of persistent bradycardia (< 60 beats/min.), heart block or recurrent unexplained syncope","risk of cardiac conduction failure, syncope and injury","Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 beats/min.), heart block or recurrent unexplained syncope (risk of cardiac conduction failure, syncope and injury)."
STOPP,Section D: Central Nervous System,18,Acetylcholinesterase inhibitors,"with concurrent treatment with drugs that induce persistent bradycardia (< 60 beats/min.) such as beta-blockers, digoxin, diltiazem, verapamil","risk of cardiac conduction failure, syncope and injury","Acetylcholinesterase inhibitors with concurrent treatment with drugs that induce persistent bradycardia (< 60 beats/min.) such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury)."
STOPP,Section D: Central Nervous System,19,Memantine,with known current or previous seizure disorder,increased risk of seizures,Memantine with known current or previous seizure disorder (increased risk of seizures).
STOPP,Section D: Central Nervous System,20,Nootropics,"in dementia including Gingko Biloba, piracetam, pramiracetam, phenylpiracetam, aniracetam, phosphatidylserine, modafinil, L-theanine, omega-3 fatty acids, panax ginseng, rhodiola, creatine",no evidence of efficacy,"Nootropics in dementia including Gingko Biloba, piracetam, pramiracetam, phenylpiracetam, aniracetam, phosphatidylserine, modafinil, L-theanine, omega-3 fatty acids, panax ginseng, rhodiola, creatine (no evidence of efficacy)."
STOPP,Section D: Central Nervous System,21,Phenothiazines as first-line treatment,"for psychosis or non-cognitive symptoms of dementia, since safer and more efficacious alternatives exist","phenothiazines are sedative, have significant anti-muscarinic toxicity in older people, except for prochlorperazine for 5 nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care","Phenothiazines as first-line treatment for psychosis or non-cognitive symptoms of dementia, since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people, except for prochlorperazine for 5 nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care)."
STOPP,Section D: Central Nervous System,22,Levodopa or dopamine agonists,for benign essential tremor,no evidence of efficacy,Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy)
STOPP,Section D: Central Nervous System,23,Levodopa or dopamine agonists,for treatment of extrapyramidal side-effects of antipsychotics or other forms of drug-induced Parkinsonism,inappropriate prescribing cascade to be avoided,Levodopa or dopamine agonists for treatment of extrapyramidal side-effects of antipsychotics or other forms of drug-induced Parkinsonism (inappropriate prescribing cascade to be avoided).
STOPP,Section D: Central Nervous System,24,First-generation antihistamines as first-line treatment,for allergy or pruritus,safer antihistamines with fewer side-effects now widely available,First-generation antihistamines as first-line treatment for allergy or pruritus (safer antihistamines with fewer side-effects now widely available).
STOPP,Section D: Central Nervous System,25,First-generation antihistamines,for insomnia,"high risk of side-effects, Z-drugs safer and more appropriate for short-term use","First-generation antihistamines for insomnia (high risk of side-effects, Z-drugs safer and more appropriate for short-term use)."
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,1,Digoxin at a long-term (i.e. more than 90 days) maintenance dose ≥ 125µg/day if eGFR < 30 ml/min/1.73m2,General/Unspecified,risk of digoxin toxicity if plasma levels not measured,Digoxin at a long-term (i.e. more than 90 days) maintenance dose ≥ 125µg/day if eGFR < 30 ml/min/1.73m2 (risk of digoxin toxicity if plasma levels not measured).
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,2,"Direct thrombin inhibitors (e.g., dabigatran) if eGFR < 30 ml/min/1.73m2",General/Unspecified,risk of bleeding,"Direct thrombin inhibitors (e.g., dabigatran) if eGFR < 30 ml/min/1.73m2 (risk of bleeding)"
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,3,"Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban) if eGFR < 15 ml/min/1.73m2",General/Unspecified,risk of bleeding,"Factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban) if eGFR < 15 ml/min/1.73m2 (risk of bleeding)"
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,4,NSAID’s if eGFR < 50 ml/min/1.73m2,General/Unspecified,risk of deterioration in renal function,NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function).
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,5,Colchicine if eGFR < 10 ml/min/1.73m2,General/Unspecified,risk of colchicine toxicity,Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity)
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,6,Metformin if eGFR < 30 ml/min/1.73m2,General/Unspecified,risk of lactic acidosis,Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis).
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,7,"Mineralocorticoid receptor antagonists (e.g. spironolactone, eplerenone) if eGFR < 30 ml/min/1.73m2",General/Unspecified,risk of dangerous hyperkalaemia,"Mineralocorticoid receptor antagonists (e.g. spironolactone, eplerenone) if eGFR < 30 ml/min/1.73m2 (risk of dangerous hyperkalaemia)."
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,8,Nitrofurantoin if eGFR < 45 ml/min/1.73m2,General/Unspecified,increased risk of nitrofurantoin toxicity,Nitrofurantoin if eGFR < 45 ml/min/1.73m2 (increased risk of nitrofurantoin toxicity).
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,9,Bisphosphonates if eGFR<30 ml/min/1.73m2,General/Unspecified,increased risk of acute renal failure,Bisphosphonates if eGFR<30 ml/min/1.73m2 (increased risk of acute renal failure).
STOPP,Section E: Renal System. The following commonly prescribed drugs are potentially,10,Methotrexate if eGFR <30 ml/min/1.73m2,General/Unspecified,increased risk of methotrexate toxicity,Methotrexate if eGFR <30 ml/min/1.73m2 (increased risk of methotrexate toxicity).
STOPP,Section F: Gastrointestinal System,1,Prochlorperazine or metoclopramide,with Parkinsonism,risk of exacerbating Parkinsonian symptoms,Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian symptoms).
STOPP,Section F: Gastrointestinal System,2,Proton pump inhibitor (PPI),for uncomplicated peptic ulcer disease at full therapeutic dosage for > 8 weeks,dose reduction or earlier discontinuation or H2 antagonist maintenance therapy usually indicated,Proton pump inhibitor (PPI) for uncomplicated peptic ulcer disease at full therapeutic dosage for > 8 weeks (dose reduction or earlier discontinuation or H2 antagonist maintenance therapy usually indicated). 6
STOPP,Section F: Gastrointestinal System,3,"Drugs likely to cause constipation (e.g. systemic antimuscarinics, oral iron, opioids, verapamil, aluminium antacids)",with chronic constipation where non-constipating alternatives are available,risk of exacerbation of constipation,"Drugs likely to cause constipation (e.g. systemic antimuscarinics, oral iron, opioids, verapamil, aluminium antacids) with chronic constipation where non-constipating alternatives are available (risk of exacerbation of constipation)."
STOPP,Section F: Gastrointestinal System,4,Oral elemental iron doses greater than 200 mg daily,General/Unspecified,"e.g. ferrous fumarate> 600 mg/day, ferrous sulphate > 600 mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced iron absorption above these doses","Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate> 600 mg/day, ferrous sulphate > 600 mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced iron absorption above these doses)."
STOPP,Section F: Gastrointestinal System,5,Corticosteroids,with a history of peptic ulcer disease or erosive oesophagitis,risk of relapse unless proton pump inhibitor is co-prescribed,Corticosteroids with a history of peptic ulcer disease or erosive oesophagitis (risk of relapse unless proton pump inhibitor is co-prescribed).
STOPP,Section F: Gastrointestinal System,6,Antiplatelet or anticoagulant drugs,"with a history of Gastric Antral Vascular Ectasia (GAVE, “watermelon stomach”)",risk of major gastrointestinal bleeding,"Antiplatelet or anticoagulant drugs with a history of Gastric Antral Vascular Ectasia (GAVE, “watermelon stomach”) (risk of major gastrointestinal bleeding)."
STOPP,Section F: Gastrointestinal System,7,Antipsychotics,with dysphagia,increased risk of aspiration pneumonia,Antipsychotics with dysphagia (increased risk of aspiration pneumonia).
STOPP,Section F: Gastrointestinal System,8,Megestrol acetate to increase appetite,General/Unspecified,increased risk of thrombosis and death with unproven efficacy,Megestrol acetate to increase appetite (increased risk of thrombosis and death with unproven efficacy)
STOPP,Section G: Respiratory System,1,Theophylline as monotherapy,for COPD,"safer, more effective alternative; risk of adverse effects due to narrow therapeutic index","Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse effects due to narrow therapeutic index)."
STOPP,Section G: Respiratory System,2,Systemic corticosteroids instead of inhaled corticosteroids,for maintenance therapy in moderate-severe COPD,unnecessary exposure to long-term side-effects of systemic corticosteroids and effective inhaled therapies are available,Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD (unnecessary exposure to long-term side-effects of systemic corticosteroids and effective inhaled therapies are available).
STOPP,Section G: Respiratory System,3,"Long-acting muscarinic antagonists (e.g., tiotropium, aclidinium, umeclidinium, glycopyrronium)",with a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction,may cause urinary retention,"Long-acting muscarinic antagonists (e.g., tiotropium, aclidinium, umeclidinium, glycopyrronium) with a history of narrow angle glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention)."
STOPP,Section G: Respiratory System,4,Benzodiazepines,with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa,risk of exacerbation of respiratory failure,Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa (risk of exacerbation of respiratory failure).
STOPP,Section H: Musculoskeletal System,1,Non-steroidal anti-inflammatory drugs (NSAIDs) other than COX-2 selective agents,"with history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist",risk of peptic ulcer relapse,"Non-steroidal anti-inflammatory drugs (NSAIDs) other than COX-2 selective agents with history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist (risk of peptic ulcer relapse)."
STOPP,Section H: Musculoskeletal System,2,NSAID’s,"with severe hypertension i.e., systolic blood pressure consistently above 170 mmHg and/or diastolic blood pressure consistently above 100 mmHg",risk of exacerbation of hypertension,"NSAID’s with severe hypertension i.e., systolic blood pressure consistently above 170 mmHg and/or diastolic blood pressure consistently above 100 mmHg (risk of exacerbation of hypertension). 7"
STOPP,Section H: Musculoskeletal System,3,Long-term use of NSAID (>3 months),for symptom relief of osteoarthritis pain where paracetamol has not been tried,simple analgesics preferable and usually as effective for pain relief and safer,Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where paracetamol has not been tried (simple analgesics preferable and usually as effective for pain relief and safer).
STOPP,Section H: Musculoskeletal System,4,Long-term corticosteroids (>3 months) as monotherapy,for rheumatoid arthritis,risk of systemic corticosteroid side-effects,Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis (risk of systemic corticosteroid side-effects).
STOPP,Section H: Musculoskeletal System,5,Corticosteroids (other than periodic intra-articular injections,for mono-articular pain) for osteoarthritis,risk of systemic corticosteroid side-effects,Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for osteoarthritis (risk of systemic corticosteroid side-effects).
STOPP,Section H: Musculoskeletal System,6,Long-term NSAID or colchicine (>3 months),"for chronic treatment of gout where there is no contraindication to a xanthine-oxidase inhibitor (e.g., allopurinol, febuxostat)",xanthine- oxidase inhibitors are first choice prophylactic drugs in gout,"Long-term NSAID or colchicine (>3 months) for chronic treatment of gout where there is no contraindication to a xanthine-oxidase inhibitor (e.g., allopurinol, febuxostat) (xanthine- oxidase inhibitors are first choice prophylactic drugs in gout)."
STOPP,Section H: Musculoskeletal System,7,NSAID,with concurrent corticosteroids for treatment of arthritis/rheumatism of any kind,increased risk of peptic ulcer disease,NSAID with concurrent corticosteroids for treatment of arthritis/rheumatism of any kind (increased risk of peptic ulcer disease).
STOPP,Section H: Musculoskeletal System,8,Oral bisphosphonates,"in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding","risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture","Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture)."
STOPP,Section H: Musculoskeletal System,9,Long-term opioids,for osteoarthritis,"lack of evidence of efficacy, increased risk of serious side-effects","Long-term opioids for osteoarthritis (lack of evidence of efficacy, increased risk of serious side-effects)."
STOPP,Section I: Urogenital System,1,"Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium)",with dementia or chronic cognitive impairment,"risk of increased confusion, agitation","Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium) with dementia or chronic cognitive impairment (risk of increased confusion, agitation)."
STOPP,Section I: Urogenital System,2,"Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium)",with narrow-angle glaucoma,risk of acute exacerbation of glaucoma,"Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium) with narrow-angle glaucoma (risk of acute exacerbation of glaucoma)."
STOPP,Section I: Urogenital System,3,"Systemic antimuscarinic (e.g., oxybutynin, tolterodine, trospium) drugs",for lower urinary tract symptoms with benign prostatic hyperplasia (BPH) and high post-void residual volume i.e. > 200 ml,uncertain efficacy and increased risk of urinary retention in older men,"Systemic antimuscarinic (e.g., oxybutynin, tolterodine, trospium) drugs for lower urinary tract symptoms with benign prostatic hyperplasia (BPH) and high post-void residual volume i.e. > 200 ml (uncertain efficacy and increased risk of urinary retention in older men)."
STOPP,Section I: Urogenital System,4,"Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium)",with constipation,risk of exacerbation of constipation,"Systemic antimuscarinic drugs (e.g., oxybutynin, tolterodine, trospium) with constipation (risk of exacerbation of constipation)."
STOPP,Section I: Urogenital System,5,"Alpha-1 receptor antagonists other than silodosin (e.g., alfuzosin, doxazosin, indoramin, tamsulosin, terazosin)",with symptomatic orthostatic hypotension or history of syncope,risk of precipitating recurrent syncope,"Alpha-1 receptor antagonists other than silodosin (e.g., alfuzosin, doxazosin, indoramin, tamsulosin, terazosin) with symptomatic orthostatic hypotension or history of syncope (risk of precipitating recurrent syncope)."
STOPP,Section I: Urogenital System,6,Mirabegron,in labile or severe hypertension,risk of exacerbation of hypertension,Mirabegron in labile or severe hypertension (risk of exacerbation of hypertension).
STOPP,Section I: Urogenital System,7,Duloxetine,with urinary urgency or urge incontinence,duloxetine is indicated in stress incontinence but not in urinary urgency or urge incontinence,Duloxetine with urinary urgency or urge incontinence (duloxetine is indicated in stress incontinence but not in urinary urgency or urge incontinence).
STOPP,Section I: Urogenital System,8,Antibiotic use,in asymptomatic bacteriuria,no indication for treatment,Antibiotic use in asymptomatic bacteriuria (no indication for treatment). 8 Section J. Endocrine System
STOPP,Section I: Urogenital System,1,Sulphonylureas,"with a long half-life (e.g., glibenclamide, chlorpropamide, glimepiride) with type 2 diabetes mellitus",risk of prolonged hypoglycaemia,"Sulphonylureas with a long half-life (e.g., glibenclamide, chlorpropamide, glimepiride) with type 2 diabetes mellitus (risk of prolonged hypoglycaemia)."
STOPP,Section I: Urogenital System,2,"Thiazolidenediones (e.g., rosiglitazone, pioglitazone)",with heart failure,risk of exacerbation of heart failure,"Thiazolidenediones (e.g., rosiglitazone, pioglitazone) with heart failure (risk of exacerbation of heart failure)."
STOPP,Section I: Urogenital System,3,Non-selective beta-blockers,in diabetes mellitus with frequent hypoglycaemic episodes,risk of suppressing hypoglycaemic symptoms,Non-selective beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of suppressing hypoglycaemic symptoms).
STOPP,Section I: Urogenital System,4,"Sodium glucose co-transporter (SGLT2) inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)",with symptomatic hypotension,risk of exacerbation of hypotension,"Sodium glucose co-transporter (SGLT2) inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) with symptomatic hypotension (risk of exacerbation of hypotension)."
STOPP,Section I: Urogenital System,5,Systemic oestrogens,with a history of breast cancer,increased risk of recurrence,Systemic oestrogens with a history of breast cancer (increased risk of recurrence).
STOPP,Section I: Urogenital System,6,Systemic oestrogens,with a history of venous thromboembolism,increased risk of recurrence,Systemic oestrogens with a history of venous thromboembolism (increased risk of recurrence).
STOPP,Section I: Urogenital System,7,Menopausal hormone therapy (oestrogen plus progestin),"with a history of stenotic coronary, cerebral or peripheral arterial disease",increased risk of acute arterial thrombosis,"Menopausal hormone therapy (oestrogen plus progestin) with a history of stenotic coronary, cerebral or peripheral arterial disease (increased risk of acute arterial thrombosis)."
STOPP,Section I: Urogenital System,8,Systemic oestrogens without progestogens,in patients with intact uterus,risk of endometrial cancer,Systemic oestrogens without progestogens in patients with intact uterus (risk of endometrial cancer).
STOPP,Section I: Urogenital System,9,Levothyroxine,"in subclinical hypothyroidism i.e., normal free T4, elevated TSH but < 10 mU/L","no evidence of benefit, risk of iatrogenic thyrotoxicosis","Levothyroxine in subclinical hypothyroidism i.e., normal free T4, elevated TSH but < 10 mU/L (no evidence of benefit, risk of iatrogenic thyrotoxicosis)."
STOPP,Section I: Urogenital System,10,"Vasopressin analogues (e.g., desmopressin, vasopressin)",for urinary incontinence or urinary frequency,risk of symptomatic hyponatraemia,"Vasopressin analogues (e.g., desmopressin, vasopressin) for urinary incontinence or urinary frequency (risk of symptomatic hyponatraemia)."
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,1,Benzodiazepines,in patients with recurrent falls,"may cause reduced sensorium, impair balance","Benzodiazepines in patients with recurrent falls (may cause reduced sensorium, impair balance)."
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,2,Antipsychotic drugs,in patients with recurrent falls,may cause Parkinsonism,Antipsychotic drugs in patients with recurrent falls (may cause Parkinsonism).
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,3,Vasodilator drugs,"in patients with recurrent falls with persistent postural hypotension i.e., systolic BP drop ≥ 20 mmHg and/or diastolic BP drop ≥ 10 mmHg","risk of syncope, falls","Vasodilator drugs in patients with recurrent falls with persistent postural hypotension i.e., systolic BP drop ≥ 20 mmHg and/or diastolic BP drop ≥ 10 mmHg (risk of syncope, falls)."
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,4,"Hypnotic Z-drugs i.e., zopiclone, zolpidem, zaleplon",in patients with recurrent falls,"may cause protracted daytime sedation, ataxia","Hypnotic Z-drugs i.e., zopiclone, zolpidem, zaleplon in patients with recurrent falls (may cause protracted daytime sedation, ataxia)."
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,5,Anti-epileptic drugs,in patients with recurrent falls,"may impair sensorium, may adversely affect cerebellar function","Anti-epileptic drugs in patients with recurrent falls (may impair sensorium, may adversely affect cerebellar function)."
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,6,First generation antihistamines,in patients with recurrent falls,may impair sensorium,First generation antihistamines in patients with recurrent falls (may impair sensorium). 9
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,7,Opioids,in patients with recurrent falls,may impair sensorium,Opioids in patients with recurrent falls (may impair sensorium).
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,8,Antidepressants,in patients with recurrent falls,may impair sensorium,Antidepressants in patients with recurrent falls (may impair sensorium).
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,9,Alpha blockers as antihypertensives,in patients with recurrent falls,may cause orthostatic hypotension,Alpha blockers as antihypertensives in patients with recurrent falls (may cause orthostatic hypotension).
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,10,Alpha blockers,"for prostatic bladder outflow symptoms, other than silodosin in patients with recurrent falls",may cause orthostatic hypotension,"Alpha blockers for prostatic bladder outflow symptoms, other than silodosin in patients with recurrent falls (may cause orthostatic hypotension)."
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,11,Centrally acting antihypertensives,General/Unspecified,may impair sensorium and may cause orthostatic hypotension,Centrally acting antihypertensives (may impair sensorium and may cause orthostatic hypotension).
STOPP,Section K: Drug classes that predictably increase falls risk in susceptible older people.,12,Antimuscarinics,for treatment of overactive bladder or urge incontinence,may impair sensorium,Antimuscarinics for treatment of overactive bladder or urge incontinence (may impair sensorium).
STOPP,Section L: Analgesic Drugs,1,"Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, methadone, tramadol, pethidine, pentazocine) as first line therapy",for mild pain,WHO analgesic ladder not observed; paracetamol or NSAID not prescribed as first-line therapy,"Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, methadone, tramadol, pethidine, pentazocine) as first line therapy for mild pain (WHO analgesic ladder not observed; paracetamol or NSAID not prescribed as first-line therapy)."
STOPP,Section L: Analgesic Drugs,2,Use of daily regular (as distinct from PRN) opioids without concomitant laxative,General/Unspecified,risk of severe constipation,Use of daily regular (as distinct from PRN) opioids without concomitant laxative (risk of severe constipation).
STOPP,Section L: Analgesic Drugs,3,Long-acting opioids without short-acting opioids,for break-through moderate or severe pain,risk of persistence of severe pain,Long-acting opioids without short-acting opioids for break-through moderate or severe pain (risk of persistence of severe pain).
STOPP,Section L: Analgesic Drugs,4,Topical lidocaine (lignocaine) patch,for treatment of chronic osteoarthritis pain,lack of evidence of efficacy,Topical lidocaine (lignocaine) patch for treatment of chronic osteoarthritis pain (lack of evidence of efficacy).
STOPP,Section L: Analgesic Drugs,5,"Gabapentinoids (e.g., gabapentin, pregabalin)",for non-neuropathic pain,lack of evidence of efficacy,"Gabapentinoids (e.g., gabapentin, pregabalin) for non-neuropathic pain (lack of evidence of efficacy)."
STOPP,Section L: Analgesic Drugs,6,Paracetamol at doses ≥ 3 g/24 hours,"in patients with poor nutritional status i.e., BMI < 18 or chronic liver disease",risk of hepatotoxicity,"Paracetamol at doses ≥ 3 g/24 hours in patients with poor nutritional status i.e., BMI < 18 or chronic liver disease (risk of hepatotoxicity)."
STOPP,Section M: Antimuscarinic/Anticholinergic Drug Burden,1,Concomitant use of two or more drugs,"with antimuscarinic/anticholinergic properties (e.g., bladder antispasmodics, intestinal antispasmodics, tricyclic antidepressants, first generation antihistamines, antipsychotics)",risk of increased antimuscarinic/anticholinergic toxicity,"Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (e.g., bladder antispasmodics, intestinal antispasmodics, tricyclic antidepressants, first generation antihistamines, antipsychotics) (risk of increased antimuscarinic/anticholinergic toxicity). 10"
START,Section A: Indicated drugs.,1,Where a drug is clearly indicated and considered appropriate,"in the particular clinical context and there is no clear contraindication, that drug should be initiated as per formulary guidelines for dose and duration.",Omission of indicated therapy,"Where a drug is clearly indicated and considered appropriate in the particular clinical context and there is no clear contraindication, that drug should be initiated as per formulary guidelines for dose and duration."
START,Section B: Cardiovascular System,1,Antihypertensive therapy,"where systolic blood pressure > 140 mmHg and /or diastolic blood pressure > 90 mmHg, unless established moderate or severe physical frailty in whom the threshold for therapy is 150 mmHg systolic pressure and/or 90 mmHg diastolic pressure.",Omission of indicated therapy,"Antihypertensive therapy where systolic blood pressure > 140 mmHg and /or diastolic blood pressure > 90 mmHg, unless established moderate or severe physical frailty in whom the threshold for therapy is 150 mmHg systolic pressure and/or 90 mmHg diastolic pressure."
START,Section B: Cardiovascular System,2,Statin therapy,"with a documented history of coronary, cerebral or peripheral vascular disease, unless the patient’s status is end-of-life or established moderate or severe frailty.",Omission of indicated therapy,"Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, unless the patient’s status is end-of-life or established moderate or severe frailty."
START,Section B: Cardiovascular System,3,Angiotensin Converting Enzyme (ACE) inhibitor,with coronary artery disease.,Omission of indicated therapy,Angiotensin Converting Enzyme (ACE) inhibitor with coronary artery disease.
START,Section B: Cardiovascular System,4,Beta-blocker,with symptomatic coronary artery disease.,Omission of indicated therapy,Beta-blocker with symptomatic coronary artery disease.
START,Section B: Cardiovascular System,5,Angiotensin Converting Enzyme (ACE) inhibitor,for heart failure with reduced ejection fraction.,Omission of indicated therapy,Angiotensin Converting Enzyme (ACE) inhibitor for heart failure with reduced ejection fraction.
START,Section B: Cardiovascular System,6,"Cardio-selective beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol)",for stable heart failure with reduced ejection fraction.,Omission of indicated therapy,"Cardio-selective beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) for stable heart failure with reduced ejection fraction."
START,Section B: Cardiovascular System,7,"Mineralocorticoid receptor antagonist (spironolactone, eplerenone)","in heart failure without severe renal function impairment i.e., eGFR > 30 ml/min/m2.",Omission of indicated therapy,"Mineralocorticoid receptor antagonist (spironolactone, eplerenone) in heart failure without severe renal function impairment i.e., eGFR > 30 ml/min/m2."
START,Section B: Cardiovascular System,8,"SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)",in symptomatic heart failure with or without reduced ejection fraction regardless of diabetes being present or not.,Omission of indicated therapy,"SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) in symptomatic heart failure with or without reduced ejection fraction regardless of diabetes being present or not."
START,Section B: Cardiovascular System,9,Sacubitril/valsartan,in heart failure with reduced ejection fraction causing persistent heart failure symptoms despite optimal dose of ACE inhibitor or Angiotensin Receptor Blocker (Sacubitril/valsartan to replace ACE inhibitor or Angiotensin Receptor Blocker).,Omission of indicated therapy,Sacubitril/valsartan in heart failure with reduced ejection fraction causing persistent heart failure symptoms despite optimal dose of ACE inhibitor or Angiotensin Receptor Blocker (Sacubitril/valsartan to replace ACE inhibitor or Angiotensin Receptor Blocker).
START,Section B: Cardiovascular System,10,Beta-blocker,for chronic atrial fibrillation with uncontrolled heart rate.,Omission of indicated therapy,Beta-blocker for chronic atrial fibrillation with uncontrolled heart rate.
START,Section B: Cardiovascular System,11,Intravenous iron,for symptomatic heart failure with reduced ejection fraction and iron deficiency. 11,Omission of indicated therapy,Intravenous iron for symptomatic heart failure with reduced ejection fraction and iron deficiency. 11
START,Section C: Coagulation System,1,Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors,in the presence of chronic or paroxysmal atrial fibrillation.,Omission of indicated therapy,Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic or paroxysmal atrial fibrillation.
START,Section C: Coagulation System,2,Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor),"with a documented history of coronary, cerebral or peripheral vascular disease.",Omission of indicated therapy,"Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history of coronary, cerebral or peripheral vascular disease."
START,Section D: Central Nervous System,1,L-DOPA or a dopamine agonist,in idiopathic Parkinson’s disease with functional impairment and resultant disability.,Omission of indicated therapy,L-DOPA or a dopamine agonist in idiopathic Parkinson’s disease with functional impairment and resultant disability.
START,Section D: Central Nervous System,2,Non-TCA antidepressant,for major depression.,Omission of indicated therapy,Non-TCA antidepressant for major depression.
START,Section D: Central Nervous System,3,"Acetylcholinesterase inhibitor (donepezil, rivastigmine, galantamine)",for mild-moderate Alzheimer’s dementia.,Omission of indicated therapy,"Acetylcholinesterase inhibitor (donepezil, rivastigmine, galantamine) for mild-moderate Alzheimer’s dementia."
START,Section D: Central Nervous System,4,Rivastigmine,for Dementia with Lewy Bodies or Parkinson’s disease dementia.,Omission of indicated therapy,Rivastigmine for Dementia with Lewy Bodies or Parkinson’s disease dementia.
START,Section D: Central Nervous System,5,Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated),for persistent severe anxiety that affects independent functioning and quality of life.,Omission of indicated therapy,Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated) for persistent severe anxiety that affects independent functioning and quality of life.
START,Section D: Central Nervous System,6,Dopamine agonist (ropinirole or pramipexole or rotigotine),"for Restless Legs Syndrome, once iron deficiency and severe chronic kidney disease (i.e., eGFR < 30 ml/min/m2) have been excluded.",Omission of indicated therapy,"Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless Legs Syndrome, once iron deficiency and severe chronic kidney disease (i.e., eGFR < 30 ml/min/m2) have been excluded."
START,Section D: Central Nervous System,7,Propranolol,for essential tremor with functional impairment and resultant disability.,Omission of indicated therapy,Propranolol for essential tremor with functional impairment and resultant disability.
START,Section E: Renal System,1,One-alpha hydroxycholecalciferol or calcitriol supplementation,"in severe chronic kidney (i.e., eGFR < 30 ml/min/m2) disease with hypocalcaemia (corrected serum calcium < 2.10 mmol/l) and associated secondary hyperparathyroidism.",Omission of indicated therapy,"One-alpha hydroxycholecalciferol or calcitriol supplementation in severe chronic kidney (i.e., eGFR < 30 ml/min/m2) disease with hypocalcaemia (corrected serum calcium < 2.10 mmol/l) and associated secondary hyperparathyroidism."
START,Section E: Renal System,2,Phosphate binder,"in severe chronic kidney disease (i.e., eGFR < 30 ml/min/m2) if serum phosphate concentration persistently >1.76 mmol/l (5.5 mg/dl) despite adherence to renal diet.",Omission of indicated therapy,"Phosphate binder in severe chronic kidney disease (i.e., eGFR < 30 ml/min/m2) if serum phosphate concentration persistently >1.76 mmol/l (5.5 mg/dl) despite adherence to renal diet."
START,Section E: Renal System,3,Erythopoietin analogue,"in severe chronic kidney disease (i.e., eGFR < 30 ml/min/m2) with symptomatic anaemia not attributable to haematinic or iron deficiency to achieve a haemoglobin concentration of 10.0 to 12.0 g/dl.",Omission of indicated therapy,"Erythopoietin analogue in severe chronic kidney disease (i.e., eGFR < 30 ml/min/m2) with symptomatic anaemia not attributable to haematinic or iron deficiency to achieve a haemoglobin concentration of 10.0 to 12.0 g/dl."
START,Section E: Renal System,4,Angiotensin receptor blocker (ARB) or Angiotensin Converting Enzyme Inhibitor (ACE-I),"in chronic kidney disease with proteinuria i.e., urine albumin excretion >300 mg/24 hours. 12",Omission of indicated therapy,"Angiotensin receptor blocker (ARB) or Angiotensin Converting Enzyme Inhibitor (ACE-I) in chronic kidney disease with proteinuria i.e., urine albumin excretion >300 mg/24 hours. 12"
START,Section F: Gastrointestinal System,1,Proton Pump Inhibitor,with severe gastro-oesophageal reflux disease or peptic oesophageal stricture requiring dilatation.,Omission of indicated therapy,Proton Pump Inhibitor with severe gastro-oesophageal reflux disease or peptic oesophageal stricture requiring dilatation.
START,Section F: Gastrointestinal System,2,Proton pump inhibitor,with initiation of low-dose aspirin and previous history of peptic ulcer or reflux oesophagitis.,Omission of indicated therapy,Proton pump inhibitor with initiation of low-dose aspirin and previous history of peptic ulcer or reflux oesophagitis.
START,Section F: Gastrointestinal System,3,Proton pump inhibitor,with short-term (< 2 weeks) or longer-term (> 2 weeks) NSAID.,Omission of indicated therapy,Proton pump inhibitor with short-term (< 2 weeks) or longer-term (> 2 weeks) NSAID.
START,Section F: Gastrointestinal System,4,"Fibre supplements (e.g., bran, ispaghula, methylcellulose, sterculia)",for diverticulosis with a history of constipation.,Omission of indicated therapy,"Fibre supplements (e.g., bran, ispaghula, methylcellulose, sterculia) for diverticulosis with a history of constipation."
START,Section F: Gastrointestinal System,5,"Osmotic laxative (e.g., lactulose, macrogol, sorbitol)",for chronic persistent idiopathic or secondary benign constipation.,Omission of indicated therapy,"Osmotic laxative (e.g., lactulose, macrogol, sorbitol) for chronic persistent idiopathic or secondary benign constipation."
START,Section F: Gastrointestinal System,6,Probiotics used,with antibiotics in patients who are not immunocompromised or severely debilitated for the prevention of Clostridioides difficile-associated diarrhoea.,Omission of indicated therapy,Probiotics used with antibiotics in patients who are not immunocompromised or severely debilitated for the prevention of Clostridioides difficile-associated diarrhoea.
START,Section F: Gastrointestinal System,7,Helicobacter pylori eradication therapy,in HP-associated active peptic ulcer disease.,Omission of indicated therapy,Helicobacter pylori eradication therapy in HP-associated active peptic ulcer disease.
START,Section G: Respiratory System,1,"Long-acting muscarinic antagonist (LAMA e.g., tiotropium, aclidinium, umeclidinium, glycopyrronium) or long-acting beta 2 agonist (LABA e.g., bambuterol, formoterol, indacaterol, olodaterol, salmeterol)",for symptomatic COPD of GOLD 1 or 2 severity and chronic asthma.,Omission of indicated therapy,"Long-acting muscarinic antagonist (LAMA e.g., tiotropium, aclidinium, umeclidinium, glycopyrronium) or long-acting beta 2 agonist (LABA e.g., bambuterol, formoterol, indacaterol, olodaterol, salmeterol) for symptomatic COPD of GOLD 1 or 2 severity and chronic asthma."
START,Section G: Respiratory System,2,"Regular i.e. daily inhaled corticosteroid (e.g., beclomethasone, budesonide, ciclesonide, fluticasone, mometasone)","for moderate-severe asthma or COPD of GOLD 3 or 4 severity, where FEV1 <50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids.",Omission of indicated therapy,"Regular i.e. daily inhaled corticosteroid (e.g., beclomethasone, budesonide, ciclesonide, fluticasone, mometasone) for moderate-severe asthma or COPD of GOLD 3 or 4 severity, where FEV1 <50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids."
START,Section G: Respiratory System,3,Home continuous oxygen,"with documented chronic hypoxaemia (i.e., pO2 < 8.0 kPa or 60 mmHg or SaO2 < 89%).",Omission of indicated therapy,"Home continuous oxygen with documented chronic hypoxaemia (i.e., pO2 < 8.0 kPa or 60 mmHg or SaO2 < 89%)."
START,Section H: Musculoskeletal System,1,Disease-modifying anti-rheumatic drug (DMARD),"with chronic, active and disabling rheumatoid arthritis.",Omission of indicated therapy,"Disease-modifying anti-rheumatic drug (DMARD) with chronic, active and disabling rheumatoid arthritis."
START,Section H: Musculoskeletal System,2,Bisphosphonates and vitamin D and calcium,in patients taking long-term systemic corticosteroid therapy for prevention of steroid-induced osteoporosis.,Omission of indicated therapy,Bisphosphonates and vitamin D and calcium in patients taking long-term systemic corticosteroid therapy for prevention of steroid-induced osteoporosis.
START,Section H: Musculoskeletal System,3,Vitamin D,in patients with known osteoporosis and/or previous fragility fracture(s) and/or Bone Mineral Density T-scores below -2.5 in one or multiple sites.,Omission of indicated therapy,Vitamin D in patients with known osteoporosis and/or previous fragility fracture(s) and/or Bone Mineral Density T-scores below -2.5 in one or multiple sites.
START,Section H: Musculoskeletal System,4,"Bone anti-resorptive or anabolic therapy (e.g., bisphosphonate, teriparatide, denosumab)",in patients with documented osteoporosis (Bone Mineral Density T-scores below -2.5 in one 13 or multiple sites) and/or previous history of fragility fracture(s) – where no pharmacological or clinical status contraindication exists such as poor one-year life expectancy.,Omission of indicated therapy,"Bone anti-resorptive or anabolic therapy (e.g., bisphosphonate, teriparatide, denosumab) in patients with documented osteoporosis (Bone Mineral Density T-scores below -2.5 in one 13 or multiple sites) and/or previous history of fragility fracture(s) – where no pharmacological or clinical status contraindication exists such as poor one-year life expectancy."
START,Section H: Musculoskeletal System,5,Vitamin D supplement,"in older people with confirmed 25-hydroxycolecalciferol deficiency (< 20 micrograms/L, < 50 nmol/L) who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is less than -1.0 but above -2.5 in one or multiple sites).",Omission of indicated therapy,"Vitamin D supplement in older people with confirmed 25-hydroxycolecalciferol deficiency (< 20 micrograms/L, < 50 nmol/L) who are housebound or experiencing falls or with osteopenia (Bone Mineral Density T-score is less than -1.0 but above -2.5 in one or multiple sites)."
START,Section H: Musculoskeletal System,6,"Anti-resorptive treatment after discontinuation of at least two doses of denosumab (rebound increased bone turnover markers, BMD loss, and increased risk of vertebral fracture following denosumab discontinuation).",Review Manually,Omission of indicated therapy,"Anti-resorptive treatment after discontinuation of at least two doses of denosumab (rebound increased bone turnover markers, BMD loss, and increased risk of vertebral fracture following denosumab discontinuation)."
START,Section H: Musculoskeletal System,7,Anti-resorptive treatment after discontinuation of teriparatide/abaloparatide treatment,for osteoporosis.,Omission of indicated therapy,Anti-resorptive treatment after discontinuation of teriparatide/abaloparatide treatment for osteoporosis.
START,Section H: Musculoskeletal System,8,"Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat)",with a history of recurrent episodes of gout.,Omission of indicated therapy,"Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat) with a history of recurrent episodes of gout."
START,Section H: Musculoskeletal System,9,Folic acid supplement,in patients taking methotrexate.,Omission of indicated therapy,Folic acid supplement in patients taking methotrexate.
START,Section I: Urogenital System,1,"Selective alpha-1 receptor blocker (e.g., tamsulosin, silodosin)",for lower urinary tract symptoms related to benign prostatic hyperplasia where prostatectomy is not considered necessary or appropriate or safe.,Omission of indicated therapy,"Selective alpha-1 receptor blocker (e.g., tamsulosin, silodosin) for lower urinary tract symptoms related to benign prostatic hyperplasia where prostatectomy is not considered necessary or appropriate or safe."
START,Section I: Urogenital System,2,"5-alpha reductase inhibitor (e.g., finasteride, dutasteride)",for lower urinary tract symptoms related to benign prostatic hyperplasia where prostatectomy is not considered necessary or appropriate or safe.,Omission of indicated therapy,"5-alpha reductase inhibitor (e.g., finasteride, dutasteride) for lower urinary tract symptoms related to benign prostatic hyperplasia where prostatectomy is not considered necessary or appropriate or safe."
START,Section I: Urogenital System,3,Topical vaginal oestrogen or vaginal oestrogen pessary,for symptomatic atrophic vaginitis.,Omission of indicated therapy,Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis.
START,Section I: Urogenital System,4,Topical vaginal oestrogen or vaginal oestrogen pessary,in women for recurrent urinary tract infections.,Omission of indicated therapy,Topical vaginal oestrogen or vaginal oestrogen pessary in women for recurrent urinary tract infections.
START,Section I: Urogenital System,5,"Phosphodiesterase type-5 inhibitors (e.g., avanafil, sildenafil, tadalafil, vardenafil)",for persistent erectile dysfunction that causes distress.,Omission of indicated therapy,"Phosphodiesterase type-5 inhibitors (e.g., avanafil, sildenafil, tadalafil, vardenafil) for persistent erectile dysfunction that causes distress."
START,Section J: Endocrine System,1,ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor),"in diabetes with evidence of renal disease i.e., dipstick proteinuria or microalbuminuria (>30 mg/24 hours) unless evidence of severe CKD (eGFR < 30 ml/min/m2).",Omission of indicated therapy,"ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal disease i.e., dipstick proteinuria or microalbuminuria (>30 mg/24 hours) unless evidence of severe CKD (eGFR < 30 ml/min/m2)."
START,Section K: Analgesics,1,High-potency opioids,"in moderate-severe non-arthritis pain, where paracetamol, NSAIDs or low-potency opioids are not appropriate to the pain severity or have been ineffective.",Omission of indicated therapy,"High-potency opioids in moderate-severe non-arthritis pain, where paracetamol, NSAIDs or low-potency opioids are not appropriate to the pain severity or have been ineffective."
START,Section K: Analgesics,2,Laxatives,"in patients receiving opioids regularly i.e., other than PRN use.",Omission of indicated therapy,"Laxatives in patients receiving opioids regularly i.e., other than PRN use."
START,Section K: Analgesics,3,Topical 5% lidocaine (lignocaine) patch,"for localized neuropathic pain, e.g. post-herpetic neuralgia.",Omission of indicated therapy,"Topical 5% lidocaine (lignocaine) patch for localized neuropathic pain, e.g. post-herpetic neuralgia."
START,Section L: Vaccines,1,Seasonal influenza vaccine annually.,Review Manually,Omission of indicated therapy,Seasonal influenza vaccine annually.
START,Section L: Vaccines,2,Pneumococcal vaccine at least once according to national guidelines.,Review Manually,Omission of indicated therapy,Pneumococcal vaccine at least once according to national guidelines.
START,Section L: Vaccines,3,Varicella-zoster vaccine according to national guidelines.,Review Manually,Omission of indicated therapy,Varicella-zoster vaccine according to national guidelines.
START,Section L: Vaccines,4,SARS-CoV2 vaccine according to national guidelines. 15,Review Manually,Omission of indicated therapy,SARS-CoV2 vaccine according to national guidelines. 15
